Cowen Inc. raised its holdings in C.R. Bard, Inc. (NYSE:BCR) by 100.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 571,487 shares of the medical instruments supplier’s stock after acquiring an additional 286,685 shares during the period. C.R. Bard makes up 6.5% of Cowen Inc.’s investment portfolio, making the stock its 5th largest position. Cowen Inc. owned about 0.78% of C.R. Bard worth $183,162,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the business. Monroe Bank & Trust MI raised its holdings in shares of C.R. Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 177 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in C.R. Bard by 70.4% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares during the period. Parallel Advisors LLC increased its stake in C.R. Bard by 2.8% in the 2nd quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 14 shares during the period. Captrust Financial Advisors purchased a new position in C.R. Bard in the 2nd quarter worth approximately $192,000. Finally, Choate Investment Advisors purchased a new position in C.R. Bard in the 2nd quarter worth approximately $201,000. 79.21% of the stock is currently owned by hedge funds and other institutional investors.
Shares of C.R. Bard, Inc. (NYSE:BCR) opened at $332.14 on Thursday. The firm has a market capitalization of $24,235.98, a P/E ratio of 28.71, a PEG ratio of 2.54 and a beta of 0.52. C.R. Bard, Inc. has a 1 year low of $206.71 and a 1 year high of $337.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is presently 13.70%.
In other C.R. Bard news, insider Timothy P. Collins sold 8,388 shares of the business’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $322.00, for a total value of $2,700,936.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Insiders have sold 191,593 shares of company stock worth $62,655,513 over the last 90 days. 0.80% of the stock is currently owned by corporate insiders.
A number of equities analysts have commented on BCR shares. Barclays lifted their price target on C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Jefferies Group reaffirmed a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Thursday, September 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Cowen reaffirmed a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Friday, November 3rd. Finally, ValuEngine lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a strong buy rating to the stock. C.R. Bard has an average rating of “Hold” and a consensus price target of $303.50.
WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3079174/c-r-bard-inc-bcr-is-cowen-inc-s-5th-largest-position.html.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.